Association of albumin, neutrophil-lymphocyte ratio and lymphocytes with clinical stage in cervical cancer patients.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-02-01 Epub Date: 2024-07-13 DOI:10.1007/s12094-024-03575-5

Elizabeth Pérez-Cruz, Luis Carlos Howlet-Caballero, Xicoténcatl Jiménez Villanueva

{"title":"Association of albumin, neutrophil-lymphocyte ratio and lymphocytes with clinical stage in cervical cancer patients.","authors":"Elizabeth Pérez-Cruz, Luis Carlos Howlet-Caballero, Xicoténcatl Jiménez Villanueva","doi":"10.1007/s12094-024-03575-5","DOIUrl":null,"url":null,"abstract":"Objective: To determinate the association between of albumin, neutrophil-lymphocyte ratio and lymphocytes (NLR) with clinical stage in cervical cancers.Methods: Design a retrospective cross-sectional study of consecutive subjects diagnosed with cervical cancer for the first time. The Bethesda system was used for histological diagnosis and the subjects were stratified with the FIGO system, considering stages IA to IIB as localized; while, IIIA and IVB as advanced stages. Albumin, NLR and lymphocytes were evaluated as inflammatory biomarkers and the cut-off points generated by the ROC curves were albumin < 3 mg/dL, NLR ≥ 2.0 and lymphocytes < 1.2 103/ul. The association was calculated by Odds Ratios (OR) with 95% confidence intervals.Results: A total of 152 patients were analyzed, with mean age of 49.3 ± 14.0 years. Epidermoid cancer was the most frequent in 70.6% and 51.3% were classified as advanced clinical stages. A bivariate analysis showed significant relationships between advanced clinical stages and albumin < 3 mg/dL with OR 5.72 (CI95% 2.62-12.4; p < 0.001); for NLR ≥ 2.0 an OR 2.53 (CI95% 1.34-4.89; p = 0.005) and for lymphocytes < 1.2 103/ul of OR 3.39 (CI95% = 1.73-6.65; p < 0.001).Conclusions: Albumin levels < 3 mg/dL, NLR ≥ 2.0 and lymphocytes < 1.2 103/ul, were associated with advanced stages in subjects with cervical cancer.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"687-692"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03575-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determinate the association between of albumin, neutrophil-lymphocyte ratio and lymphocytes (NLR) with clinical stage in cervical cancers.

Methods: Design a retrospective cross-sectional study of consecutive subjects diagnosed with cervical cancer for the first time. The Bethesda system was used for histological diagnosis and the subjects were stratified with the FIGO system, considering stages IA to IIB as localized; while, IIIA and IVB as advanced stages. Albumin, NLR and lymphocytes were evaluated as inflammatory biomarkers and the cut-off points generated by the ROC curves were albumin < 3 mg/dL, NLR ≥ 2.0 and lymphocytes < 1.2 10³/ul. The association was calculated by Odds Ratios (OR) with 95% confidence intervals.

Results: A total of 152 patients were analyzed, with mean age of 49.3 ± 14.0 years. Epidermoid cancer was the most frequent in 70.6% and 51.3% were classified as advanced clinical stages. A bivariate analysis showed significant relationships between advanced clinical stages and albumin < 3 mg/dL with OR 5.72 (CI95% 2.62-12.4; p < 0.001); for NLR ≥ 2.0 an OR 2.53 (CI95% 1.34-4.89; p = 0.005) and for lymphocytes < 1.2 10³/ul of OR 3.39 (CI95% = 1.73-6.65; p < 0.001).

Conclusions: Albumin levels < 3 mg/dL, NLR ≥ 2.0 and lymphocytes < 1.2 10³/ul, were associated with advanced stages in subjects with cervical cancer.

Abstract Image

查看原文本刊更多论文

宫颈癌患者的白蛋白、中性粒细胞-淋巴细胞比率和淋巴细胞与临床分期的关系

目的确定白蛋白、中性粒细胞-淋巴细胞比率和淋巴细胞（NLR）与宫颈癌临床分期之间的关系：对首次诊断为宫颈癌的连续受试者进行回顾性横断面研究。组织学诊断采用 Bethesda 系统，受试者按 FIGO 系统进行分层，IA 至 IIB 期为局部分期，IIIA 和 IVB 期为晚期分期。白蛋白、NLR 和淋巴细胞作为炎症生物标志物进行评估，ROC 曲线得出的临界点为白蛋白 3/ul。两者之间的相关性通过带95%置信区间的比值比（OR）进行计算：共分析了 152 名患者，平均年龄（49.3 ± 14.0）岁。70.6%的患者为表皮样癌，51.3%的患者为临床晚期。双变量分析显示，晚期临床分期与白蛋白 3/ul之间存在显著关系，OR 值为 3.39（CI95% = 1.73-6.65；P 结论：白蛋白 3/ul水平与晚期临床分期之间存在显著关系：白蛋白水平 3/ul与宫颈癌患者的晚期分期有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.